- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 207/14 - Nitrogen atoms not forming part of a nitro radical
Patent holdings for IPC class C07D 207/14
Total number of patents in this class: 419
10-year publication summary
|
19
|
32
|
31
|
25
|
41
|
23
|
22
|
22
|
19
|
28
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Takeda Pharmaceutical Company Limited | 2721 |
36 |
| Bristol-myers Squibb Company | 4826 |
16 |
| The Regents of the University of California | 20303 |
12 |
| Taisho Pharmaceutical Co., Ltd. | 869 |
12 |
| Mission Therapeutics Limited | 80 |
10 |
| Oryzon Genomics S.A. | 108 |
9 |
| ADT Pharmaceuticals, LLC | 13 |
9 |
| F. Hoffmann-La Roche AG | 7937 |
8 |
| H. Lundbeck A/S | 1237 |
7 |
| Merck Sharp & Dohme LLC | 3732 |
7 |
| Janssen Pharmaceutica N.V. | 3358 |
6 |
| Dana-Farber Cancer Institute, Inc. | 2626 |
6 |
| Theravance Biopharma R&D IP, LLC | 453 |
6 |
| Engrail Therapeutics, Inc. | 17 |
6 |
| Mitsubishi Tanabe Pharma Corporation | 560 |
5 |
| Tetraphase Pharmaceuticals, Inc. | 51 |
5 |
| Sanofi | 4140 |
5 |
| President and Fellows of Harvard College | 6043 |
4 |
| Kinki University | 247 |
4 |
| Nektar Therapeutics | 437 |
4 |
| Other owners | 242 |